$ROIV
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Healthcare
Sector
Biotechnology
Industry
Matthew Gline
CEO
908
Employees
$27.70
Current Price
$19.67B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 2 | $6,848,573.48 | 241,861 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 2 | $6,848,573.48 | 241,861 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 3 | $23,007,672.38 | 829,251 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 7 | 22 | $201,146,591.63 | 7,458,654 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 8 | 29 | $249,735,149.19 | 9,671,253 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Feb 13, 2026 | QVT Financial LP Director by Deputization | Sale | 150,784 | $26.49 | $3,994,268.16 | View Details |
| Feb 9, 2026 | Sukhatme Mayukh Director | Sale | 339,441 | $26.47 | $8,985,003.27 | View Details |
| Jan 12, 2026 | Venker Eric President & Immunovant CEO | Sale | 200,000 | $21.92 | $4,384,000.00 | View Details |
| Dec 29, 2025 | Sukhatme Mayukh Director | Sale | 311,873 | $21.74 | $6,780,119.02 | View Details |
| Dec 31, 2025 | Sukhatme Mayukh Director | Sale | 1,018,995 | $21.71 | $22,122,381.45 | View Details |
| Dec 23, 2025 | Pulik Richard CFO | Sale | 146,731 | $22.39 | $3,285,307.09 | View Details |
| Dec 23, 2025 | Pulik Richard CFO | Sale | 260,000 | $22.45 | $5,837,000.00 | View Details |
| Dec 24, 2025 | Venker Eric President & Immunovant CEO | Sale | 75,000 | $22.53 | $1,689,750.00 | View Details |
| Dec 23, 2025 | Venker Eric President & Immunovant CEO | Sale | 200,000 | $22.45 | $4,490,000.00 | View Details |
69 more transactions available โ create a free account to see 12 months of history | ||||||
Showing 21โ29 of 29 transactions
Upcoming Earnings
Scheduled earnings reports
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated-$0.27
ActualN/A
Revenue
Estimated$6.14M
ActualN/A
EPS
Estimated-$0.27
ActualN/A
Revenue
Estimated$6.14M
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history